|
Published by: SMI Publishing, Ltd
Published: May. 23, 2005
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Jorgen Petersen, Senior Medical Director, Genmab A/S.
- 9.10 KEYNOTE ADDRESS
- Current trends in the treatment of arthritis
- Recent findings in novel therapeutic targets
- Assessing the drug classes currently on the market
- Predictions for the future of arthritis treatment
- Raising awareness of clinical trial results and issues in drug safety
- Professor David Isenberg, Academic Director, Rheumatology, University College London.
- 9.50 THE FUTURE OF COX-2
- A strategic assessment
- Understanding the regulatory guidelines and implications
- Assessing the impact on the market
- Optimising future agents
- The future of COX-2’s
- Ms Clare Churchill, Healthcare Analyst, Datamonitor.
- 10.30 Morning Coffee
- 11.00 PANEL DISCUSSION
- COX-2 inhibitors v NSAIDs
- Assessing the findings of the study
- Will the axe fall on COX-2’s?
- Predictions for 2005 and beyond
- Mrs Melissa Stolper, Research Analyst, Decision Resources, Inc.
- Professor David Isenberg, Academic Director, Rheumatology, University College London.
- Dr Christian Antoni, Group irector, Clinical Immunology, Schering Plough.
- 11.40 MARKET OPPORTUNITIES FOR RHEUMATOID ARTHRITIS DRUGS
- The changing face of the Rheumatoid Arthritis market
- Future trends in RA epidemiology
- Current treatment options and medical practice
- Unmet needs and untapped areas of opportunity
- Emerging therapies and their potential impact on the RA treatment paradigm
- Market dynamics and the future outlook for the RA market
- Mrs Melissa Stolper, Research Analyst, Decision Resources, Inc.
- 12.20 Networking Lunch
- 1.50 DRUG DISCOVERY IN RHEUMATOID ARTHRITIS TREATMENT
- Key developments and future trends
- The current situation with anti-TNF and the implications for alternative drugs
- Current treatment options
- Combination therapies and trial results
- Development opportunities
- Dr Stephen Myers, Medical Director, Musculoskeletal Programs, Eli Lilly & Company.
- 2.30 REMICADE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
- A case study
- Feasibility of TNF alpha treatment
- The associated benefits of the drug
- Raising expectations in results
- Looking to the future of anti-zytokine treatment
- 3.10 Afternoon Tea
- 3.40 NOVEL DRUG USE IN RHEUMATOID ARTHRITIS
- P38 inhibitors for the treatment of RA
- Identification
- Potency & selectivity
- Metabolism & Pharmacokinetics
- Anti-inflammatory activity in-vivo
- Dr Adrian Moore, Senior Inflammation Pharmacologist, UCB-Celltech.
- 4.20 DRUG DEVELOPMENT IN RA - RhuDex
- Changing the face of RA treatment
- Development of the first-in-class small molecule CD80
- New orally available drug for RA
- Novel ‘co-stimulation’ modifier
- Assessing the outlook for RA treatment
- Dr Neill MacKenzie, CBO, Avidex.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Jorgen Petersen, Senior Medical Director, Genmab A/S.
- 9.10 THE IDENTIFICATION OF PROTEIN BIOMARKERS
- Innovative approaches
- Early detection of rheumatoid arthritis
- Details of the study and the implications
- The role of drug development
- The effect on clinical trials
- Dr Elena Izmailova, Scientist, Millennium Pharmaceuticals.
- 9.50 ORAL THERAPY FOR RHEUMATOID ARTHRITIS
- New class of TNF-a inhibitors
- Discovery of new class of TNF-a inhibitors with novel mechanism of action
- In vitro and in vivo effects on LPS induced TNF-a production
- Efficacy in rodent models of inflammation and RA
- Analgesic activity
- Preclinical development and in vivo effects on LPS induced
- Dr Mladen Mercep, Inflammation-Immunology Programs Director, PLIVA.
- 10.30 Morning Coffee
- 11.00 MRI
- Quantitative image analysis in osteoarthritis
- Image analysis technology for OA
- Quantitative cartilage image-based biomarkers
- Quantitative non-cartilage image-based biomarkers
- Clinical trials in OA using quantitative MRI image analysis
- Dr Saara Totterman, Chief Medical Officer, Virtual Scopics L L C.
- 11.40 BINDING IMMUNOGLOBULIN PROTEIN (BIP)
- Developments and discoveries
- Updates on what has been learnt in the last year
- Assessing the associated benefits of the treatment
- Meeting the needs of the research and patient
- Professor Gabriel Panayi, ARC Professor, Rhuematology, Department of Rheumatology, Kings College London.
- 12.20 Networking Lunch
- 1.50 SMALL MOLECULE KINASE
- The potential of small molecule kinase inhibitors as anti-arthritic agents
- Overview of kinase pathways involved
- Potential kinase targets
- Data from preclinical models of arthritis
- Dr Heather Raymon, Associate Director, In Vivo Pharmacology, Celgene.
- 2.30 DRUG DEVELOPMENT IN THE TREATMENT OF OA
- CINOD: a new class of drugs for the treatment of OA pain
- Role of nitric oxide (NO) in gastrointestinal and cardiovascular systems
- Discovery of CINODs (Cox Inhibiting Nitric Oxide Donators)
- Profile of the lead compound HCT 3012
- Clinical data in osteoarthritis (OA) pain
- Clinical data on gastrointestinal and cardiovascular safety
- CINOD: a unique opportunity in the new environment
- Dr Ennio Ongini, Head, Research , Nicox.
- 3.10 Afternoon Tea
- 3.40 DRUG SCREENING
- The importance of investigating immune responses in vivo
- Why it is important to screen immunomodulators in vivo
- How to screen immunomodulators in vivo
- Recent advances in screening immunomodulators in vivo
- The future of screening immunomodulators in vivo
- Professor Paul Garside, Member, Scientific Board, MD Biosciences.
- 4.20 PANEL DISCUSSION
- The future of anti-arthritic agents
- What progress is being made?
- Where the potential problems lie
- How will treatment be affected in the future?
- The next stage of development
- Mr Neil Gozzard, Director, Pharmacology, UCB-Celltech.
- Dr Stephen Myers, Medical Director, Musculoskeletal Programs, Eli Lilly & Company.
- Dr Mladen Mercep, Inflammation-Immunology Programs Director, PLIVA.
- Dr Elena Izmailova, Scientist, Millennium Pharmaceuticals.
- 5.00 Chairman’s Closing Remarks and Close of Day Two
AbstractIt had been predicted that the market for anti-arthritic drugs would exceed more than $20 billion in the next few years. However, with recent safety concerns over the use of Cox-2 inhibitors, the growth of this market has become a topic of great controversy, with the future development and use of Non-Steroidal Anti-Inflammatory (NSAIDs) being somewhat uncertain.
To learn more, join us for the opportunity to discuss the latest issues surrounding the current arthritis market, including updates on both existing and novel treatments available, illustrative case studies examining the strategies of all the major players in the auto-immunity field and the future of Cox-2 inhibitors. Hear from leading experts from major pharmaceutical companies and serious academic leaders as they assess the latest enthusiasm for DMARD therapy, including the potential for combination treatment, advances in target identification and validation and the development of novel anti-arthritic drugs. This event will also consider the latest regulatory guidelines, updates on research and effective clinical trial design for both osteo and rheumatoid arthritis.
A unique opportunity to learn from leading industry experts including:
- Dr Stephen Myers, Acting Medical Director, Musculoskeletal Programs, Eli Lilly
- Dr Christian Antoni, Group Director, Clinical Immunology, Schering-Plough
- Dr Heather Raymon, Associate Director, in vivo Pharmacology, Celgene
- Adrian Moore, Senior Inflammation Pharmacologist, Celltech
- Dr Elena Izmailova, Scientist, Millennium Pharmaceuticals
- Professor David Isenberg, Academic Director, Rheumatology, University College London
- Professor Gabriel Panayi, ARC Professor, Rheumatology, King’s College London
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
